Enterprise Value

151.8B

Cash

8.73B

Avg Qtr Burn

N/A

Short % of Float

1.77%

Insider Ownership

0.07%

Institutional Own.

78.21%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Sotyktu (deucravacitinib) Details
Psoriasis, Skin disease/disorder

Approved

Quarterly sales

Eliquis Details
Stroke, Atrial fibrillation, Blood clots

Approved

Quarterly sales

Opdivo® (nivolumab) + chemotherapy Details
Cancer, Non-small cell lung carcinoma

Approved

Quarterly sales

Reblozyl®(luspatercept-aamt) Details
Cancer, Blood cancer, Mutant Myelodysplastic Syndromes, Anemia

Approved

Quarterly sales

Camzyos®(mavacamten) Details
Hypertrophic cardiomyopathies

Approved

Quarterly sales

PDUFA

Approval decision

Repotrectinib (ROS1/TRK inhibitor) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

PDUFA

Approval decision

PDUFA

Approval decision

Milvexian Details
Stroke, Atrial fibrillation, Acute coronary syndrome

Phase 3

Data readout

Phase 3

Update

Phase 3

Update

Opdivo® (nivolumab) + Yervoy (ipilimumab) Details
Non-small cell lung carcinoma, Cancer

Phase 3

Update

BMS-986278 [(LPA1) antagonist] Details
Idiopathic pulmonary fibrosis, Lung disease

Phase 3

Initiation

Breyanzi® (lisocabtagene maraleucel) Details
Blood cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia

Phase 2

Data readout

A/I CELMoD (CC-99282) Details
Non-Hodgkin lymphoma, Cancer, Relapsed/ refractory lymphoma

Phase 2

Interim update

Breyanzi® (lisocabtagene maraleucel) Details
B-cell lymphoma, Non-Hodgkin lymphoma, Follicular lymphoma

Phase 2

Update

Phase 2

Initiation

Phase 1/2

Update

Breyanzi® (lisocabtagene maraleucel) Details
Non-Hodgkin lymphoma, B-cell lymphoma, Mantle cell lymphoma

Phase 1

Update